Fig. 1: Patient inclusion and baseline characteristics.
From: ctDNA-based molecular residual disease and survival in resectable colorectal cancer
a, CONSORT diagram illustrating the inclusion of patients from enrollment to primary and subanalyses in this study. b, Patient characteristics of the evaluable patient population (n = 2,240). EDC, electronic data capture; RX, the presence of residual tumor cannot be assessed.
